2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1547 Olverembatinib combined with lisaftoclax demonstrates deep remissions and central nervous system (CNS) penetration in pediatric relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (R/R Ph+ ALL)

Jingliao Zhang, MD, PhD, Junxia Wang2, Tianfeng Liu3, Xiaoyan Zhang4, Ranran Zhang5, Min Ruan6, Lixian Chang, MD7, Xiaoming Liu8, Yuanyuan Ren9, Xia Chen10, Huanshan Guo, MD11, Hengbang Wang, MD, PhD12, Yingchi Zhang13, Yumei Chen14, Li Zhang15, Ye Guo16, Fang Liu17, Xiaojuan Chen18, Yao Zou19, Wenyu Yang20, Yifan Zhai, MD, PhD21, Xiaofan Zhu, MD22
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
11 Guangzhou Healthquest Pharma Co., Ltd., Guangzhou, China
12 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
16 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
17 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
18 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
19 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
20 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
21 Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, China, Ascentage Pharma Group Inc., Rockville, Maryland, United States, Guangzhou Healthquest Pharma Co., Ltd., Guangzhou, China
22 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

Background

Ph+ ALL in children remains a high-risk disease particularly after tyrosine kinase inhibitor (TKI) failure or acquisition of BCR::ABL1 kinase domain (KD) mutations. Olverembatinib is a potent 3G TKI with activity against resistant BCR::ABL1 variants, including T315I and compound mutations. Lisaftoclax is a selective BCL-2 inhibitor with synergistic antileukemic activity when combined with TKIs in preclinical models. We report safety, efficacy, pharmacokinetic (PK), and CNS penetration results from a study evaluating olverembatinib plus lisaftoclax in pediatric R/R Ph+ ALL.

Methods

This multicenter open-label phase 1b study enrolled patients ages <18 with R/R Ph+ ALL resistant or intolerant to ≥1 TKI. Patients received olverembatinib 40 mg adult-equivalent dose (AED) every other day on days 1-14, followed by combination therapy with lisaftoclax (200, 400, or 600 mg AED daily with a 3-day dose ramp-up) and dexamethasone (6 mg/m²/day, days 15-42). Primary endpoints included safety, tolerability, dose-limiting toxicities, and recommended phase 2 dose (RP2D). Secondary endpoints included morphologic response, cytogenetic response, MRD (via flow cytometry), PK, and CNS penetration. Morphologic responses were assessed via standard ALL response criteria. Cytogenetic responses were evaluated by BCR::ABL1 fluorescence in situ hybridization (FISH), with complete cytogenetic response defined as ≤1% BCR::ABL1-positive nuclei. Molecular response was assessed by quantitative PCR for BCR::ABL1 transcripts, including major molecular response (MMR; BCR::ABL1/ABL1 ≤0.1%) and complete molecular response (CMR; undetectable BCR::ABL1 transcripts with adequate assay sensitivity). Plasma and CSF concentrations of olverembatinib and lisaftoclax were evaluated after repeated dosing.

Results

As of July 7, 2026, 18 patients were treated with olverembatinib 40 mg AED combined with lisaftoclax 600 mg AED. The median age was 13.0 years (range, 9-17). Fourteen patients (77.8%) had p190 BCR::ABL1 transcripts, and 6 (33.3%) had ABL1 KD mutations, including T315I (n=4), L248V (n=1), and F317L (n=1). Treatment-related adverse events (TRAEs) occurred in 17/18 patients (94.4%), with grade ≥3 TRAEs in 11/18 (61.1%). Frequent grade ≥3 TRAEs included neutrophil count decreased (38.9%), white blood cell count decreased (38.9%), anemia (16.7%), and platelet count decreased (16.7%). Hepatic laboratory abnormalities occurred in 7 patients (38.9%), including grade ≥3 events in 4 (22.2%). Two patients discontinued treatment because of AEs (1 seizure and 1 hepatic toxicity). No treatment-related deaths occurred. Among 10 patients evaluable for morphologic response, the overall response rate (CR+CRi) increased from 60.0% (6/10) after olverembatinib monotherapy to 90.0% (9/10) with combination therapy (C2D15), and all responders achieved CR. Among 13 evaluable patients on C1D14, MRD negativity increased from 30.8% (4/13) after olverembatinib monotherapy to 69.2% (9/13) at C2D15 and was maintained at C2D28. MMR or deeper responses were achieved in 56.4% (9/16) of evaluable patients after combination therapy, including those with baseline ABL1 KD mutations. Olverembatinib showed sustained exposure, with a median Tmax of ~6 hours and a terminal elimination half-life of ~13-16 hours, without apparent accumulation on repeated dosing. Lisaftoclax demonstrated dose-related exposure across the 200-600 mg AED range, with a terminal half-life of ~4-6 hours and no significant accumulation. No clinically meaningful drug-drug interaction (DDI) was observed between the two agents. Olverembatinib was detectable in all evaluable CSF samples (9/9), with CSF-to-plasma concentration ratios ranging from 0.046%-0.37%. No apparent CSF accumulation was observed with repeated administration. Lisaftoclax was detectable in 4/9 CSF samples, with CSF-to-plasma ratios ranging from 0.025%-0.133%. Further data on CSF PK are not available.

Conclusions

Updated results from this study demonstrate that olverembatinib plus lisaftoclax induces rapid and deep molecular responses, with manageable toxicity, in pediatric patients with R/R Ph+ ALL, including those with high-risk ABL1 KD mutations. Comprehensive PK analyses confirmed predictable systemic exposure, absence of clinically relevant DDIs, and measurable CNS penetration by both agents. These findings support further clinical development of this oral, chemotherapy-free, targeted regimen as a promising strategy for high-risk pediatric Ph+ ALL.

Jingliao Zhang, MD, PhD: No relevant conflicts of interest to declare.